Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multimodal Railway Vibration and Vision Dataset (Rail-VIVID).

Scientific data·2026
Same author

Multi-Scale Tri-Modal Histology Dataset Integrating Tumor Morphology, Immune Patterns, and Clinical Outcomes.

bioRxiv : the preprint server for biology·2026
Same author

Life expectancy estimation in older men using the prostate cancer comorbidity index in VA & SEER-Medicare cohorts.

Age and ageing·2026
Same author

Erratum to "Establishing and characterizing the molecular profiles, cellular features, and clinical utility of a patient-derived xenograft model using benign prostatic tissues" (Lab Invest 2024 Oct;104(10):102129).

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Identification of serum protein biomarkers for clear cell renal cell carcinoma using patient-derived xenografts.

The Journal of clinical investigation·2026
Same author

CDC7 is a targetable regulator of advanced prostate cancer.

Scientific reports·2025
Same journal

Letter to the Editor Regarding "Microbial Differences in Prostate Lesions Between Black and White American Men".

The Prostate·2026
Same journal

Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.

The Prostate·2026
Same journal

Hematological Inflammation Markers in the Prediction of Clinically Significant Prostate Cancer and the Individualization of Biopsy Decisions for PI-RADS 3 Lesions: A Two-Center Retrospective Study.

The Prostate·2026
Same journal

Enhancing Continence Recovery After Robot-Assisted Radical Prostatectomy: A Novel Combined Approach Using Testosterone Therapy and Magnetic Stimulation.

The Prostate·2026
Same journal

Comprehensive Characterization of Metastatic Patterns and a Redefined Prognostic Framework in Metastatic Prostate Cancer.

The Prostate·2026
Same journal

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

The Prostate·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K

Biologic differences between peripheral and transition zone prostate cancer.

J Joy Lee1, I-Chun Thomas, Rosalie Nolley

  • 1Department of Urology, Stanford University School of Medicine, Stanford, California.

The Prostate
|October 21, 2014
PubMed
Summary
This summary is machine-generated.

Prostate cancer in the transition zone (TZ) shows favorable pathology and reduced recurrence risk, even with higher PSA levels. This finding highlights the importance of cancer location in risk stratification for prostatectomy patients.

Keywords:
peripheral zone prostate cancerprostate neoplasmsprostate specific antigenprostatectomytransition zone prostate cancer

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.5K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K

Related Experiment Videos

Last Updated: Apr 21, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.5K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K

Area of Science:

  • Urology
  • Oncology
  • Medical Imaging

Background:

  • Prostate cancer originates in the transition zone (TZ) in 20-25% of cases.
  • Advances in imaging and biopsy protocols increase focus on TZ prostate cancers.
  • Investigating TZ vs. peripheral zone (PZ) prostate cancer for outcome differences.

Purpose of the Study:

  • To compare transition zone (TZ) and peripheral zone (PZ) prostate cancer.
  • To determine if cancer location is independently associated with patient outcomes.
  • To analyze the impact of tumor location on adverse pathologic features and recurrence.

Main Methods:

  • Evaluated 1354 men undergoing radical prostatectomy (1983-2003).
  • Used regression models to compare cancer volume and grade by location.
  • Assessed associations between cancer location, adverse pathologic features, and recurrence using logistic and proportional hazard models.

Main Results:

  • TZ cancers presented with higher PSA and total cancer volume.
  • TZ cancers showed decreased odds of seminal vesicle invasion, extra-capsular extension, and lymphovascular invasion.
  • TZ cancers were independently associated with a decreased hazard of tumor recurrence.

Conclusions:

  • Transition zone (TZ) prostate cancer is linked to favorable pathology and better recurrence-free survival.
  • Despite higher PSA and larger volumes, TZ cancers have better outcomes.
  • Tumor location is crucial for risk stratification before and after prostatectomy, especially with evolving imaging.